(4S)-Brivaracetam-d7

(4S)-Brivaracetam-d7 is a deuterated form of the medication Brivaracetam, which is primarily used for the treatment of epilepsy. Brivaracetam is a selective high-affinity ligand for synaptic vesicle protein 2A (SV2A) that modulates neurotransmitter release in the brain. This medication is effective in managing partial-onset seizures in adults and adolescents over the age of 16. (4S)-Brivaracetam-d7 is an isotopically labeled version of Brivaracetam, which means that seven hydrogen atoms in the molecule have been replaced with their heavier isotope, deuterium. This modification does not change the pharmacological effects of the medication, but it can be useful in pharmacokinetic studies. The use of isotopically labeled drugs can help researchers to better understand the absorption, distribution, metabolism, and excretion of the medication in the body. The chemical formula for (4S)-Brivaracetam-d7 is C11H8D7N3O2S, and its molecular weight is 276.4 g/mol. The medication is typically administered orally as a tablet or solution. The recommended dosage for Brivaracetam varies depending on the age and weight of the patient, as well as the severity of their epilepsy. Common side effects of Brivaracetam include drowsiness, dizziness, and nausea. In some cases, more serious side effects such as allergic reactions and behavioral changes may occur. It is important to consult with a healthcare professional before starting any new medication.